Level Four Advisory Services’s Supernus Pharmaceuticals SUPN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-21,011
Closed -$761K 847
2023
Q1
$761K Buy
21,011
+887
+4% +$34.1K 0.05% 338
2022
Q4
$718K Sell
20,124
-7,423
-27% -$258K 0.05% 318
2022
Q3
$932K Buy
27,547
+2,369
+9% +$77.1K 0.09% 217
2022
Q2
$728K Buy
25,178
+9,959
+65% +$285K 0.07% 273
2022
Q1
$492K Buy
15,219
+1,138
+8% +$34.9K 0.04% 397
2021
Q4
$411K Buy
+14,081
New +$427K 0.03% 450

Other funds holding SUPN

Level Four Advisory Services's SUPN Position: Q2 2023 in Review

Level Four Advisory Services sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 21,011 shares — an estimated $761K sold.

Level Four Advisory Services first reported a position in SUPN in Q4 2021 and held it in 6 quarters. The position peaked at $932K in Q3 2022. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.

  • Level Four Advisory Services reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Level Four Advisory Services sold 21,011 Supernus Pharmaceuticals shares in Q2 2023, an estimated $761K.
  • Level Four Advisory Services first reported a position in Supernus Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Level Four Advisory Services's Supernus Pharmaceuticals position peaked at $932K in Q3 2022.
  • 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.

Based on Level Four Advisory Services's 13F filing for Q2 2023, filed 10 Jul 2023.